Tarsa Therapeutics (Philadelphia, PA) a clinical-stage biopharmaceutical company focused on treatments for postmenopausal osteoporosis, closed a $28 Series B financing. Participants include Foresite Capital, Novo, MVM Life Science Partners and Quaker Partners.